Venner PneuX™ System reduces the risk of ventilator-associated pneumonia (VAP) in ventilated patients – ITT selected product (#2565)

Creation
Draft
Initial
Detailed
Accepted
Adoption
Idea Description
Supplementary Information
Innovation 'Elevator Pitch':
The unique PneuX™ System monitors the endotracheal or tracheostomy tube’s seal. It measures cuff pressure and continuously adjusts itself to seal the patient’s trachea to prevent ventilator-associated pneumonia (VAP) during mechanical ventilation.
Overview of Innovation:
The PneuX™ System is for airway management in critically ill patients receiving mechanical ventilation. The system is designed to prevent ventilator-associated pneumonia (VAP) by minimising the risk of pulmonary aspiration and micro-aspiration of bacteria-contaminated subglottic secretions in patients having prolonged ventilation. The silicone material of the tube and cuff has been specifically designed to overcome the problems which cause VAP with standard endotracheal tubes, such as folds and creases in the inflatable cuff, loss of seal due to patient or tube movement and maintenance of cuff pressure. The PneuX™ System permits subglottic irrigation and drainage to remove infective material.

VAP - The problem
In the UK each year, 100,000 patients are admitted to critical care units for mechanical ventilation, and of these patients, 10-20% will develop ventilator associated pneumonia. Patients who develop VAP have an increased length of stay on ICU and increased mortality rate; of these 10,000 – 20,000 patients who develop VAP, between 3,000 and 6,000 per each year die in the UK with this type of pneumonia.
VAP is the leading nosocomial cause of mortality in ICU and the most common cause of VAP is aspiration of contaminated secretions from the oropharyngeal space. Aspiration occurs passed standard tubes or cuffs by three mechanisms:
  • Channels or invaginations within the inflated cuff
  • Movement of the cuff
  • Loss of cuff pressure

The costs of treating VAP are significant, between £10,000 and £20,000 per patient. As such, conservative estimates for prevention are savings to the NHS of over £100 million and this does not account for savings from the associated reduced length of stay.

The Solution
The PneuX™ System promotes patient safety through a five-pronged approach:
  • Reduced cuff leakage
  • Maintenance of cuff pressure
  • Convenient drainage and irrigation of subglottic secretions
  • Prevention of tube movement and accidental extubation
  • Potential inhibition of biofilm formation in tube lumen

The PneuX™ System is thus designed to produce an optimal seal and improve airway management to prevent VAP in ventilated patients in ICU or during prolonged major surgery.

The PneuX™ System attracts the Innovation and Technology Tariff (ITT), and as such is zerocost to provider Trusts to implement. Thus, as well as improving patient safety for patients in critical care, the use of this innovation will provide a cost saving for the Trust over the life of the ITT.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
Similar Content
No similar content found
6
1
Votes
-99999

Created by

Share and Follow